Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Say NO to Novartis!

March 19, 2012

Novartis, the Swiss-based pharmaceutical giant, continues its assault on India's generic pharmaceutical industry -- legally challenging India's patent law that allows the nation to supply nearly 80% of the developing world's access to high-quality, affordable, life-saving medications.

India's patent law effectively stops evergreening, a tactic used by pharmaceutical companies to make minor tweaks on medications to extend their stranglehold on a patent that is about to expire.

Should Novartis succeed on March 28th, a dangerous precedent will be set ...

With a chain-reaction of serious consequences.

View Full Article


  
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Visit HIV Prevention Justice Alliance's website to find out more about their activities and publications.
 
See Also
More Calls to Action

Reader Comments:

Comment by: michael (los angeles) Sat., Mar. 24, 2012 at 5:43 am EDT
and yet more proof that HIV is a profitable business. big pharma doesn't want to kill us, they want to kill us slowly. they don't want to cure us, there is no profit in it. curing us is the same as killing us.....no profit. wake up people. these people have deep pockets to pay off every single vote and influential people to turn a blind eye.

DON'T TREAT US. CURE US!
Reply to this comment


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement